# Zydus Lifesciences 表示將以總價1.66億美元收購美國製藥公司 Assertio Holdings。

*biotech, business · news · 2026-05-14 · Outlook Business*

## Key points

- Zydus Lifesciences 將以全現金交易方式，斥資1.664億美元收購 Assertio Holdings。
- 此收購使 Zydus 擁有以 Assertio 產品組合為核心的美國專科腫瘤商業平台。
- 交易將透過每股23.50美元的公開收購要約執行，隨後進行合併。
- Zydus 計劃利用 Assertio 的商業基礎設施，強化其在美國腫瘤領域的布局。

Zydus Lifesciences on Wednesday said it will acquire US-based pharma firm Assertio Holdings for a total consideration of USD 166.4 million (approximately Rs 1,590 crore). Zydus Worldwide DMCC, a subsidiary of the company, has signed a definitive agreement, through its wholly-owned acquisition arm Zara Merger Sub Inc, with Assertio Holdings Inc to acquire all outstanding shares of Assertio for USD 23.50 per share in cash, Zydus Lifesciences Ltd said in a statement. It represents total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method, it added. The acquisition provides Zydus with an established US speciality oncology commercial platform, anchored by Assertio's presence in oncology supportive care, the statement said. "This transaction represents a strategic step in strengthening our speciality and oncology footprint in the US. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable speciality businesses globally," Zydus Lifesciences MD Sharvil P Patel said. Zydus said it intends to leverage Assertio's focused commercial infrastructure and oncology relationships to build and expand its speciality oncology presence in the US. Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock, the statement said. After the successful completion of the tender offer, Zydus will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price paid in the tender offer, it added. The tender offer is expected to commence within five business days, following the date of the merger agreement, the company said.

**Companies:** Zydus Lifesciences, Assertio Holdings
**Countries:** United States, India

[Read the full story on Outlook Business](https://www.outlookbusiness.com/corporate/zydus-lifesciences-to-acquire-assertio-for-1664-million)

---

Canonical: https://newsio.io/zh-TW/n/7d266c0a-daa8-4f0b-80ed-352b29a252e9/zydus-lifesciences-1-66-assertio-holdings
Summarized by Newsio from Outlook Business. https://newsio.io/how-it-works